|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM204019117 |
| 003 |
DE-627 |
| 005 |
20250212063726.0 |
| 007 |
tu |
| 008 |
231223s2010 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0680.xml
|
| 035 |
|
|
|a (DE-627)NLM204019117
|
| 035 |
|
|
|a (NLM)21122200
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Fang, Yu-qiang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effects of lipid-modulation and antiplatelet treatment on the endothelial lipase expression
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.01.2012
|
| 500 |
|
|
|a Date Revised 25.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To investigate the effects of lipid-modulation and antiplatelet treatment on the expression of endothelial lipase (EL) of patients with coronary artery disease (CAD), and investigate the role of EL in the development of CAD
|
| 520 |
|
|
|a METHODS: One hundred and fifty-seven cases were divided into three groups according to clinical manifestations and the results of coronary artery angiography: control group (n=41) with more than one risk factors of CAD and the vessel lesions was <30%; stable angina pectoris (SAP) group (n=55); acute coronary syndrome (ACS) group (n=61). The EL positive cell rate was measured 2 weeks after cessation of lipid-modulation and aspirin treatment, and 6 months after treatment with simvastatin and/or aspirin. The drug was ceased for the complications or not tolerance for the treatment
|
| 520 |
|
|
|a RESULTS: Except the patients in control group with aspirin treatment, the EL positive cell rate was significantly decreased among other groups [control group with simvastatin: (3.93±0.87)% vs. (5.28±1.05)%, SAP group: (8.16±2.11)% vs. (15.12±2.53)%, ACS group: (13.93±3.22)% vs. (38.44±4.36)%; SAP group with aspirin: (10.57±4.07)% vs. (14.66±2.29)%, ACS group: (18.28±5.14)% vs. (40.27±3.96)%; control group with aspirin and simvastatin: (3.13±0.87)% vs. (5.33±1.25)%, SAP group: (5.68±2.20)% vs. (14.89±2.15)%, ACS group: (7.81±3.96)% vs. (39.27±5.17)%, P<0.05 or P<0.01]
|
| 520 |
|
|
|a CONCLUSION: The treatment with lipid-modulation and/or antiplatelet drug may significantly decrease the expression of EL, implying that EL participates in the progression of CAD
|
| 650 |
|
4 |
|a Controlled Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Hypolipidemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Simvastatin
|2 NLM
|
| 650 |
|
7 |
|a AGG2FN16EV
|2 NLM
|
| 650 |
|
7 |
|a LIPG protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.1.3
|2 NLM
|
| 650 |
|
7 |
|a Lipase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.1.3
|2 NLM
|
| 700 |
1 |
|
|a He, Duo-fen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Cheng-ming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xu-kai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zeng, Chun-yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Hong-yong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fu, Chun-jiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Wei-bin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Ye
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
|d 1998
|g 22(2010), 11 vom: 30. Nov., Seite 663-5
|w (DE-627)NLM098227793
|x 1003-0603
|7 nnns
|
| 773 |
1 |
8 |
|g volume:22
|g year:2010
|g number:11
|g day:30
|g month:11
|g pages:663-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 22
|j 2010
|e 11
|b 30
|c 11
|h 663-5
|